Q1 2025 saw a major tech breakthrough for Mantex, enabling new bioenergy market access, but revenue fell sharply and losses widened. Financing was strengthened via warrants, and commercial rollout of Biomass Analyzer 2 is planned for late 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.